Our Response to COVID-19

As the global situation surrounding COVID-19 continues to evolve, we remain committed to the researchers, patients and caregivers involved in our clinical development programs, including our planned pivotal study for congenital myotonic dystrophy (DM1). The safety of patients and families, as well as the healthcare workers and clinical trial investigators working with us in these efforts, is our primary concern. As we continue to monitor developments related to COVID-19 closely, we look forward to updating you with our plans regarding the initiation of our DM1 study and our other activities as soon as circumstances allow. If you have questions, please contact .